DAN L. LONGO, M.D.; ROBERT C. YOUNG, M.D.; SUSAN M. HUBBARD, R.N.; MARGARET WESLEY, Ph.D.; RICHARD I. FISHER, M.D.; ELAINE JAFFE, M.D.; COSTAN BERARD, M.D.; VINCENT T. DeVITA Jr., M.D.
Seventy-nine patients with nodular mixed lymphoma were treated at the National Cancer Institute between 1966 and 1978. Fifteen patients had stage I or II disease, and 64, stage III or IV disease. The overall complete response rate for the patients that received various primary treatment regimens was 76%, with 52% of complete responders remaining in their first remission at a median follow-up of 7 years. Median survival of complete responders is projected to be more than 13 years. Median survival of patients who do not achieve complete remission is less than 2 years. Patients with B symptoms, bone marrow involvement, or a lactate dehydrogenase level greater than 250 U/mL had significantly shorter survivals than did patients without these features. Patients with advanced-stage (III and IV) nodular mixed lymphoma had a 72% complete response rate, with the average remission lasting more than 6 years. Although relapses have been seen up to 8 years after diagnosis in patients with nodular mixed lymphoma given C-MOPP chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisone), prolonged initial remissions can be achieved with this therapy.
Learn more about subscription options.
Register Now for a free account.
LONGO DL, YOUNG RC, HUBBARD SM, WESLEY M, FISHER RI, JAFFE E, et al. Prolonged Initial Remission in Patients with Nodular Mixed Lymphoma. Ann Intern Med. 1984;100:651–656. doi: 10.7326/0003-4819-100-5-651
Download citation file:
Published: Ann Intern Med. 1984;100(5):651-656.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only